I'm a bit of a broken record when it comes to personal security on the internet: Make strong passwords for each account; never reuse any passwords; and sign up for two-factor authentication whenever ...

Have you ever asked an AI for a password? When you do, it quickly generates one, telling you confidently that the output is strong. In reality, it's anything but, according to research shared ...

Have you ever had Apple Passwords generate a new password that didn’t end up being saved correctly? Sometimes a website crashes at the wrong moment, or uses protocols that don’t exactly play nice with ...

Stop putting your API keys everywhere ...

6 Best Open Source Password Managers for Windows in 2026 Your email has been sent Discover the best open-source password managers for Windows in 2026, and compare ...

Every reused or weak password puts you at risk. I'm here to show you how to keep your accounts safe from hackers, phishing, and identity theft by using a password manager. I review privacy tools like ...

iOS 26 is packed with big and small changes, three of which have enabled me to make Apple’s Passwords app my one and only password manager. Three iOS 26 features have enabled me to use Apple Passwords ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Researchers say they’ve discovered a supply-chain attack flooding repositories with malicious packages that contain invisible code, a technique that’s flummoxing traditional defenses designed to ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...